GoldenGolden
Advanced Search
Sanofi Pasteur

Sanofi Pasteur

Sanofi Pasteur is a manufacturer of vaccines and related products founded in 1914 by Marcel Mérieux.

Sanofi Pasteur manufactures and exports vaccines and related products for 20-26 different diseases including malaria, meningitis B, dengue fever, pneumococcal diseases, cytomegalovirus, chlamydia and HIV. Sanofi has been focused on increasing manufacturing capacity for recombinant influenza vaccine since 2019. Sanofi has owned the company Protein Sciences since 2017.

History

Sanofi Pasteur Limited was founded in 1914 and was formerly Connaught Laboratories Limited of Toronto. Sanofi is the leading supplier of vaccines in Canada. Sanofi Pasteur’s parent company is the pharmaceutical company, Sanofi-aventis. Sanofi Pasteur was the first Canadian organization to produce antitoxins and vaccines for rabies, diphtheria, tetanus and smallpox. In the 1950s, then known as Connaught, the company had a key role in the development to polio vaccine known as the Salk vaccine and continues to produce the Salk vaccine based on killed virus and also the Sabin vaccine based on the attenuated polio virus.

Sanofi Pasteur was sold by University of Toronto to the Canada Development Corporation in 1972 and acquired by Pasteur Mérieux Serums et Vaccins, a subsidiary of Rhône Poulenc of France, in 1989. The Canadian operations changed its name from Pasteur Mérieux Connaught to Aventis Pasteur Limited in 1999. The parent company, Aventis, was acquired by Sanofi-Synthelabo, forming Sanofi-aventis.

Products

Sanofi Pasteur produced the A H1N1 swiine flu vaccine in 2009.

Sanofi will partner with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine for the new coronavirus causing the COVID-19 outbreak. Sanofi plans to use their recombinant DNA platform for the task expects the vaccine to need about one year to 18 months until it is ready for testing. The company previously developed vaccines for SARS, caused by a different strain of coronavirus. The platform Sanofi will use for the COVID-19 vaccine produces a genetic code for proteins of a virus that can serve as antigens. These are recombined with a non-dangerous virus that will produce large quantities of antigen. The antigens are separated and collected form infected cells and purified.

Translate Bio began a collaboration and exclusive licensing agreement with Sanofi Pasteur in 2018 to develop mRNA vaccines for up to five infectious disease pathogens.Translate Bio is producing mRNA constructs and will use its RNA platform to discover, design and manufacture SARS-CoV-2 vaccine candidates to treat COVID-19. The company will partner with Sanofi Pasteur who will provide expertise and support to further advance vaccine candidates.

Sanofi and Regeneron are conducting clinical trials for their IL-6 inhibitor antibody called Kevzara (sarilumab), a drug already used to treat rheumatoid arthritis, for treatment of severe cases of COVID-19. The treatment has the potential to calm an overactive immune response.

Timeline

September 27, 2016
Sanofi Pasteur raises a $43,200,000 grant from Biomedical Advanced Research and Development Authority.

Funding rounds

People

Name
Role
LinkedIn

Maria Manuela Rebola

Advisor

Xavier Marcadé

Advisor

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Sanofi
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research has granted approval to Sanofi Pasteur, the vaccines...
Sanofi
June 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- VaxelisTM (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine),...
May 27, 2021
The Economic Times
If the trial is successful, regulators could approve the vaccine for use in the last three months of the year, the drugmakers said in a statement. Their statement quoted Thomas Triomphe, who leads vaccine research and development at Sanofi Pasteur, as saying: "We are encouraged to see first vaccinations starting to take place in such an important, pivotal Phase 3 study."
May 27, 2021
The Economic Times
If the trial is successful, regulators could approve the vaccine for use in the last three months of the year, the drugmakers said in a statement. Their statement quoted Thomas Triomphe, who leads vaccine research and development at Sanofi Pasteur, as saying: "We are encouraged to see first vaccinations starting to take place in such an important, pivotal Phase 3 study."
May 27, 2021
The Economic Times
If the trial is successful, regulators could approve the vaccine for use in the last three months of the year, the drugmakers said in a statement. Their statement quoted Thomas Triomphe, who leads vaccine research and development at Sanofi Pasteur, as saying: "We are encouraged to see first vaccinations starting to take place in such an important, pivotal Phase 3 study."
May 27, 2021
The Economic Times
If the trial is successful, regulators could approve the vaccine for use in the last three months of the year, the drugmakers said in a statement. Their statement quoted Thomas Triomphe, who leads vaccine research and development at Sanofi Pasteur, as saying: "We are encouraged to see first vaccinations starting to take place in such an important, pivotal Phase 3 study."
BioSpace
May 5, 2021
BioSpace
Core One Labs Inc., is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd., as Chief Medical Officer of the Company.
BioSpace
May 28, 2020
BioSpace
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of a Commercial Advisory Board consisting of leading experts in public health policy, epidemiology, and vaccine development. The Commercial Advisory Board will work closely with VBI's management team on pre-commercialization and comm
Helen Branswell
February 18, 2020
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.